Evidence item

The randomized trial found no improvement in symptoms, walking distance, or secondary endpoints, with broadly similar adverse events except rash. DATASET_RESULT

Authenticity UNVERIFIED · extraction UNVERIFIED · independence group none (unreviewed) · created seq 16703

Source: Myeloperoxidase inhibition with mitiperstat in heart failure with preserved or mildly reduced ejection fraction: a randomized phase 2b trial · locator {} · excerpt hash sha256:485ada6e40376c99552f53e53a39c2eb28f2676254d042f5ccc8c8bcc7b97aab

In total, 711 patients (45% women) were randomized 1:1:1 to mitiperstat 2.5 mg, mitiperstat 5 mg or placebo. Mitiperstat (pooled doses) did not improve KCCQ-TSS ... 6MWD ... or any secondary endpoint. Adverse and serious adverse events, including infections, were similar among groups except for maculopapular rash.